Fatty acids, C14-18 and C16-18 unsatd., compds. with triethanolamine

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2018

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2018

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

GLP compliance:

yes

Test material

Test material information

1

Reference substance name:

Fatty acids, C14-18 and C16-18 unsatd., compds. with triethanolamine

EC Number:

268-369-2

EC Name:

Fatty acids, C14-18 and C16-18 unsatd., compds. with triethanolamine

Cas Number:

68082-25-7

Molecular formula:

Not applicable (UVCB substance)

IUPAC Name:

Fatty acids, C14-18 and C16-18 unsatd., compds. with triethanolamine

Test material form:

liquid

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

corn oil

Duration of treatment / exposure:

7 days per week for a maximum period of 63 days, i.e. during 14 days of pre-mating and maximum 14 days of mating in both males and females. Then in females, treatment will be done during the gestation period and up to post-natal day 12. Males will be dosed after the mating period until the minimum total dosing period of 28 days is completed.

Frequency of treatment:

7 days per week

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

100 mg/kg bw/day (nominal)

Remarks:

LD

Doses / concentrations 2

Dose / conc.:

300 mg/kg bw/day (nominal)

Remarks:

MD

Doses / concentrations 3

Dose / conc.:

1 000 mg/kg bw/day (nominal)

Remarks:

HD

No. of animals per sex per dose:

Group 1 (C, control): 0 mg/kg bw/day. 10 males and 10 females.
Group 2 (LD, low dose): 100 mg/kg bw/day. 10 males and 10 females.
Group 3 (MD, medium dose): 300 mg/kg bw/day. 10 males and 10 females.
Group 4 (HD, high dose): 1000 mg/kg bw/day. 10 males and 10 females.

Control animals:

yes, concurrent no treatment

Results and discussion

Results of examinations

Clinical signs:

effects observed, non-treatment-related

Description (incidence and severity):

In this study there were no clinical findings related to a systemic effect of the test item.
During the weekly detailed clinical observation, no significant changes or differences between the groups were found.
Female number 55 of the LD group was observed with the clinical findings of pale skin, hypothermia, half eyelid closure, moderate piloerection, and slow movements on post-natal day 0. However, these signs were not assumed to be test item-related but to be result of the abortion of pregnancy.
The finding of wound in two males of the HD group (male number 37: wound on snout, male number 40 wound on the head) were not considered to be test item-related.

Mortality:

mortality observed, non-treatment-related

Description (incidence):

One female of the LD group (No. 55) was euthanized on post-natal day 0 due to animal welfare reasons

Body weight and weight changes:

no effects observed

Description (incidence and severity):

The test item had no effect on body weight development in this study. Body weights of male and female animals were in the normal range of variation throughout the treatment period of this study.

Food consumption and compound intake (if feeding study):

no effects observed

Description (incidence and severity):

The test item had no effect on food consumption in this study. Mean daily food intake of male and female animals was in the normal range of variation throughout the treatment period of this study.

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

no effects observed

Description (incidence and severity):

The test item had no toxicologically relevant effect on haematology and blood coagulation parameters analysed at the end of the treatment period of this study.
Besides, all haematological parameters were within the normal range of historical data variation. Differences between the animals are due to the natural occurring inter-individual variation and are not assumed to be biologic ally relevant.
Blood coagulation was not affected by the test item as the individual values were within the normal range of variation for this strain.

Clinical biochemistry findings:

no effects observed

Description (incidence and severity):

The test item had no toxicologically relevant effect on parameters of clinical biochemistry analysed at the end of the treatment period of this study.
All parameters of clinical chemistry were within the normal range of variation for this strain and without biological relevance.

Urinalysis findings:

effects observed, non-treatment-related

Description (incidence and severity):

The test item had no significant or toxicologically relevant effect on urinary parameters analysed at the end of the treatment period of this study.
One female of the MD group (number 24) showed an elevated level of erythrocytes in the urine. This was considered to be blood contamination during urine sampling and not related to treatment with the test item.
Further, one male of the LD group (number 59) was observed with a high level of ketones and one male of the MD group (number 68) showed a high level of protein in the urine. Both findings were considered to be incidental and not to be test item-related.

Behaviour (functional findings):

not examined

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

effects observed, non-treatment-related

Description (incidence and severity):

The test item had no toxicologically relevant effect on organ weights determined at the end of the treatment period of this study.
Mean pituitary weight was slightly higher in test item-treated males compared to the control group (deviation of LD from control: 13 %, deviation of MD from control: 38 %, deviation of HD from control: 27 %). Mean pituitary weight however, was slightly lower in females treated with TEA Trioleate compared to the corresponding control (deviation of LD from control: -17 %, deviation of MD from control: -24 %, deviation of HD from control: -16 %). As the effect on mean pituitary weight shows no dose-dependency and consistency between males and females, it is not assumed to be toxicologically relevant.
Mean thyroid/parathyroid weight was slightly higher in females of the MD group (deviation from control: 24 %) compared to the corresponding control group. However, this effect is not considered test item-related as mean thyroid/parathyroid weight was not affected in all other test item-treated groups.
Mean ovary weight was slightly lower in females of the HD group compared to the control group (deviation from control: 15 %). This difference is not assumed to be toxicologically relevant as female reproductive organs undergo variable inter-individual changes depending on the stage of the estrous cycle.
Slightly higher mean thymus weight of males of the HD group (deviation from control: 14 %) and slightly higher mean thymus weight of females of the LD group (deviation from control: 16 %) were considered as incidental and not related to treatment with the test item as this effect does not follow a dose-dependency and consistency when compared with respective control groups of males and females.

Gross pathological findings:

effects observed, non-treatment-related

Description (incidence and severity):

No specific gross pathological changes were recorded for male and female animals, except for a few females which were not considered to be treatment-related.
Single findings like kidney cyst (MD male number 24), a mass in the abdominal cavity (MD female number 25), a red spotted thymus (LD female number 58), an abnormally colored pancreas (red; HD female number 73), and an abnormally colored pancreas (red) and an abnormally shaped papillary process of the liver (MD female number 68) were incidental and are not assumed to be related to treatment with the test item.
Female number 55 which was euthanized on post-natal day 0 with clinical signs of abortion was observed with an abnormal content (dark) in stomach, duodenum, jejunum, ileum, and cecum. Further, the uterus was found containing a placenta indicating the birth process of this animal. However, the findings observed in this single female were not considered to be test item-related.

Neuropathological findings:

not examined

Histopathological findings: non-neoplastic:

not examined

Histopathological findings: neoplastic:

not examined

Other effects:

not examined

Effect levels

Key result

Dose descriptor:

NOAEL

Effect level:

>= 1 000 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: no effects treatment-related observed

Remarks on result:

not determinable due to absence of adverse toxic effects

Target system / organ toxicity

Critical effects observed:

no

Applicant's summary and conclusion

Conclusions:

No treatment related effects were observed up the maximum dose tested. NOAEL >= 1000 mg/kg bw/day